BP
VRTX icon

Ballentine Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Ballentine Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Sell
5,245
-2
-0% -$886 0.03% 182
2026
Q1 		$2.34M Sell
5,247
-43
-0.8% -$20.1K 0.03% 180
2025
Q4 		$2.4M Buy
5,290
+200
+4% +$86.2K 0.03% 169
2025
Q3 		$1.99M Sell
5,090
-338
-6% -$141K 0.03% 196
2025
Q2 		$2.42M Sell
5,428
-409
-7% -$188K 0.04% 168
2025
Q1 		$2.83M Buy
5,837
+247
+4% +$115K 0.05% 135
2024
Q4 		$2.25M Buy
5,590
+119
+2% +$55.2K 0.04% 157
2024
Q3 		$2.54M Buy
5,471
+123
+2% +$59.1K 0.04% 143
2024
Q2 		$2.51M Buy
5,348
+470
+10% +$204K 0.05% 131
2024
Q1 		$2.04M Buy
4,878
+309
+7% +$131K 0.04% 151
2023
Q4 		$1.86M Buy
4,569
+201
+5% +$74.3K 0.04% 149
2023
Q3 		$1.52M Buy
4,368
+892
+26% +$312K 0.04% 149
2023
Q2 		$1.22M Buy
3,476
+131
+4% +$44.1K 0.03% 179
2023
Q1 		$1.05M Buy
3,345
+893
+36% +$268K 0.03% 189
2022
Q4 		$708K Buy
2,452
+436
+22% +$133K 0.02% 226
2022
Q3 		$584K Buy
2,016
+504
+33% +$145K 0.02% 224
2022
Q2 		$426K Buy
1,512
+131
+9% +$35.1K 0.02% 261
2022
Q1 		$360K Sell
1,381
-279
-17% -$66.2K 0.01% 314
2021
Q4 		$364K Buy
+1,660
New +$323K 0.01% 333
2021
Q3 		– Sell
-1,023
Closed -$206K – 438
2021
Q2 		$206K Sell
1,023
-84
-8% -$17.6K 0.01% 398
2021
Q1 		$238K Sell
1,107
-128
-10% -$28.1K 0.01% 343
2020
Q4 		$291K Sell
1,235
-227
-16% -$52.1K 0.01% 291
2020
Q3 		$398K Buy
1,462
+16
+1% +$4.41K 0.02% 232
2020
Q2 		$420K Sell
1,446
-49
-3% -$13.3K 0.02% 226
2020
Q1 		$356K Buy
1,495
+84
+6% +$19.3K 0.02% 227
2019
Q4 		$309K Buy
1,411
+58
+4% +$11.7K 0.01% 296
2019
Q3 		$230K Sell
1,353
-8
-0.6% -$1.42K 0.01% 347
2019
Q2 		$250K Buy
+1,361
New +$238K 0.01% 321
2017
Q4 		– Sell
-1,825
Closed -$277K – 426
2017
Q3 		$277K Sell
1,825
-3
-0.2% -$452 0.02% 287
2017
Q2 		$295K Buy
+1,828
New +$220K 0.02% 279

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Ballentine Partners's VRTX Position: Q2 2026 in Review

Ballentine Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 0.04% in Q2 2026, selling an estimated $886 and leaving 5,245 shares worth $2.61M. The position accounts for 0.03% of the portfolio, ranked #182.

Ballentine Partners first reported a position in VRTX in Q2 2017 and has held it in 30 quarters since. The position peaked at $2.83M in Q1 2025. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ballentine Partners held 5,245 shares of Vertex Pharmaceuticals worth $2.61M as of Q2 2026.
  • Ballentine Partners sold 2 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886.
  • Vertex Pharmaceuticals made up 0.03% of Ballentine Partners's portfolio in Q2 2026, its #182 holding.
  • Ballentine Partners first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 30 quarters since.
  • Ballentine Partners's Vertex Pharmaceuticals position peaked at $2.83M in Q1 2025.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.